Analyst Price Targets — OVID
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 14, 2026 12:54 pm | — | Roth Capital | $7.00 | $2.82 | TheFly | Ovid Therapeutics price target raised to $7 from $5 at Roth Capital |
| April 9, 2026 10:08 am | — | H.C. Wainwright | $4.00 | $2.88 | TheFly | Ovid Therapeutics price target raised to $4 from $2 at H.C. Wainwright |
| December 11, 2025 10:14 am | Boobalan Pachaiyappan | Roth Capital | $3.00 | $1.63 | TheFly | Ovid Therapeutics initiated with a Buy at Roth Capital |
| November 24, 2025 11:17 am | — | H.C. Wainwright | $2.00 | $1.40 | TheFly | Ovid Therapeutics price target raised to $2 from $1.50 at H.C. Wainwright |
| July 2, 2024 6:42 am | Raghuram Selvaraju | H.C. Wainwright | $3.00 | $0.86 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Ovid Therapeutics Inc (OVID) |
| May 20, 2024 5:32 am | Thomas Shrader | BTIG | $11.00 | $3.14 | StreetInsider | BTIG Reiterates Buy Rating on Ovid Therapeutics Inc (OVID) |
| May 14, 2024 3:13 pm | Francois Brisebois | Oppenheimer | $8.00 | $3.23 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Ovid Therapeutics Inc (OVID) |
Latest News for OVID
BlackRock Inc. bought a new position in shares of Ovid Therapeutics (NASDAQ: OVID) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,823,480 shares of the company's stock, valued at approximately $29,115,000. BlackRock Inc. owned 5.80% of Ovid Therapeutics
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.06 per share a year ago.
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the second quarter ended June 30, 2026.
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OVID.
U.S. House Trading
No House trades found for OVID.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.